Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Highly Heterogeneous Cellular Composition and Neighborhood Architecture within the Follicular Lymphoma Tumor Microenvironment

Paul R Buckley, Julie Chan, Cynthia Bishop, Timothy Woo, Katrina Todd, Elizabeth Phillips, Alessia Bottos, Christopher R. Bolen, Verena Passerini, Oliver Weigert, Piers E.M. Patten

Blood (2024) 144 (Supplement 1): 4382.

https://doi.org/10.1182/blood-2024-209877

Published: 2024

Journal Articles

High Grade B-Cell Lymphoma with BCL2 and MYC Rearrangement (Double-Hit High-Grade Lymphoma; DH-HGL): Establishment of a Human Model System for Ex Vivo and In Vivo Studies

Alisa Maier, Lukas Ulrich, Binje Vick, William David Keay, Johannes Adrian Hildebrand, Carolin Dorothea Strobl, Verena Passerini, Louisa Adolph, Michael Heide, Tabea Felicitas Freyholdt, Gerulf Hänel, Axel Lechner, Susanne Thieme, Leon Kaulen, Louisa von Baumgarten, Daniel J Hodson, Martina Rudelius, Irmela Jeremias, Oliver Weigert

Blood (2024) 144 (Supplement 1): 2957.

https://doi.org/10.1182/blood-2024-194493

Published: 2024

Journal Articles

Real-World Evidence of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide with or without Polatuzumab (VIPOR(P)) for Relapsed/Refractory Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 6494.

https://doi.org/10.1182/blood-2024-200002

Published: 2024

Journal Articles

Lysosomal Membrane Permeabilization Sensitizes Ctss-Hyperactive Tumors to BCL2-Targeting Therapies

Blood (2023) 142 (Supplement 1): 4358.

https://doi.org/10.1182/blood-2023-174384

Published: 2023

Journal Articles

Identification of High-Risk Population in First-Line Follicular Lymphoma at Screening with a Next Generation Sequencing (NGS) Assay Using Plasma Circulating Tumor DNA (ctDNA): Initial Data from Gallium

Alessia Bottos, Corinna Woestmann, Christopher R. Bolen, Maria Shin, Patrick Bogard, Ehsan Tabari, Andrew S. Davies, Andrea Knapp, Tina Nielsen, Oliver Weigert, Elicia Penuel

Blood (2023) 142 (Supplement 1): 1629.

https://doi.org/10.1182/blood-2023-181723

Published: 2023

Journal Articles

Genomic profiling for clinical decision making in lymphoid neoplasms

Laurence de Leval, Ash A. Alizadeh, P. Leif Bergsagel, Elias Campo, Andrew Davies, Ahmet Dogan, Jude Fitzgibbon, Steven M. Horwitz, Ari M. Melnick, William G. Morice, Ryan D. Morin, Bertrand Nadel, Stefano A. Pileri, Richard Rosenquist, Davide Rossi, Itziar Salaverria, Christian Steidl, Steven P. Treon, Andrew D. Zelenetz, Ranjana H. Advani, Carl E. Allen, Stephen M. Ansell, Wing C. Chan, James R. Cook, Lucy B. Cook, Francesco d’Amore, Stefan Dirnhofer, Martin Dreyling, Kieron Dunleavy, Andrew L. Feldman, Falko Fend, Philippe Gaulard, Paolo Ghia, John G. Gribben, Olivier Hermine, Daniel J. Hodson, Eric D. Hsi, Giorgio Inghirami, Elaine S. Jaffe, Kennosuke Karube, Keisuke Kataoka, Wolfram Klapper, Won Seog Kim, Rebecca L. King, Young H. Ko, Ann S. LaCasce, Georg Lenz, José I. Martin-Subero, Miguel A. Piris, Stefania Pittaluga, Laura Pasqualucci, Leticia Quintanilla-Martinez, Scott J. Rodig, Andreas Rosenwald, Gilles A. Salles, Jesus San-Miguel, Kerry J. Savage, Laurie H. Sehn, Gianpietro Semenzato, Louis M. Staudt, Steven H. Swerdlow, Constantine S. Tam, Judith Trotman, Julie M. Vose, Oliver Weigert, Wyndham H. Wilson, Jane N. Winter, Catherine J. Wu, Pier L. Zinzani, Emanuele Zucca, Adam Bagg, David W. Scott

Blood (2022) 140 (21): 2193–2227.

https://doi.org/10.1182/blood.2022015854

Published: 2022

Includes: Supplemental data

Journal Articles

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

Blood (2022) 140 (10): 1104–1118.

https://doi.org/10.1182/blood.2022015956

Published: 2022

Includes: Supplemental data

Journal Articles

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Blood (2021) 138 (24): 2499–2513.

https://doi.org/10.1182/blood.2020010543

Published: 2021

Includes: Supplemental data

Journal Articles

An EZH2 Gene Expression Signature Is Predictive of Differential Efficacy of Chemotherapy Irrespective of EZH2 Mutation Status in Patients with Follicular Lymphoma Treated within the Gallium Trial

Verena Passerini, Vindi Jurinovic, Christopher R Bolen, Andrea Knapp, Alessia Bottos, Julia Richter, Jude Fitzgibbon, Wolfram Klapper, Andrew Davies, Robert Marcus, Michael von Bergwelt, Tina Nielsen, Martin H. Dreyling, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Oliver Weigert

Blood (2021) 138 (Supplement 1): 39.

https://doi.org/10.1182/blood-2021-147751

Published: 2021

Journal Articles

Treatment-Free Intervals during CD19xCD3 BiTE ® Construct-Mediated T-Cell Stimulation Induce Functional Reinvigoration and Transcriptional Reprogramming of Exhausted T Cells

Blood (2021) 138 (Supplement 1): 513.

https://doi.org/10.1182/blood-2021-150178

Published: 2021

Journal Articles

ARID1A Controls a Novel Transcriptional Network Regulating FAS in Follicular Lymphoma

Martina Antoniolli, Maria Solovey, Deepak Bararia, Carolin Dorothea Strobl, William David Keay, Johannes Adrian Hildebrand, Michael Heide, Verena Passerini, Lucas Wange, Wolfgang Enard, Susanne Thieme, Helmut Blum, Martina Rudelius, Sebastian Bultmann, Heinrich Leonhardt, Marion Subklewe, Michael von Bergwelt, Maria Colomé-Tatché, Oliver Weigert

Blood (2021) 138 (Supplement 1): 3492.

https://doi.org/10.1182/blood-2021-148862

Published: 2021

Journal Articles

Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (NCT#03269669): SWOG S1608

Paul M. Barr, Hongli Li, Brian K. Link, Christopher R. Flowers, Richard Burack, Heiko Schöder, Michael L. Leblanc, Oliver Weigert, Alex F. Herrera, David M. Weinstock, John P. Leonard, Brad S. Kahl, Sonali M. Smith, Jonathan W. Friedberg

Blood (2021) 138 (Supplement 1): 2425.

https://doi.org/10.1182/blood-2021-146182

Published: 2021

Journal Articles

CHOP but Not Bendamustine Reverses EZH2 Y641 Mutation Induced MHC-I/II Loss in Human Lymphoma Models

Louisa Catharina Adolph, Quentin Fichaux, Carolin Dorothea Strobl, Martina Antoniolli, Verena Passerini, William David Keay, Vindi Jurinovic, Axel Lechner, Daniel J. Hodson, Michael von Bergwelt, Marion Subklewe, Martina Rudelius, Oliver Weigert

Blood (2021) 138 (Supplement 1): 2391.

https://doi.org/10.1182/blood-2021-144803

Published: 2021

Journal Articles

An Inducible Leukemia-Associated Transcription Factor Facilitates Large-Scale Ex Vivo Generation of Functional Human Macrophages

Blood (2021) 138 (Supplement 1): 2805.

https://doi.org/10.1182/blood-2021-148336

Published: 2021

Journal Articles

Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma

Christopher R. Bolen, Federico Mattiello, Michael Herold, Wolfgang Hiddemann, Sarah Huet, Wolfram Klapper, Robert Marcus, Farheen Mir, Gilles Salles, Oliver Weigert, Tina Nielsen, Mikkel Z. Oestergaard, Jeffrey M. Venstrom

Blood (2021) 137 (19): 2704–2707.

https://doi.org/10.1182/blood.2020008119

Published: 2021

Includes: Supplemental data

Journal Articles

Treatment-Free Intervals Mitigate T-Cell Exhaustion Induced By Continuous CD19xCD3-BiTE® Construct Stimulation in Vitro

Nora Zieger, Alyssa Nicholls, Jan Wulf, Gerulf Hänel, Maryam Kazerani Pasikhani, Veit Buecklein, MD, Bettina Brauchle, Anetta Marcinek, Daniel Nixdorf, Lisa Rohrbacher, Michaela Scheurer, Roman Kischel, MD, Karsten Spiekermann, MD, Oliver Weigert, MD, Sebastian Theurich, MD, Michael von Bergwelt, MD PhD, Marion Subklewe, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-137421

Published: 2020

Journal Articles

The different flavors and splices of MCL

Oliver Weigert

Blood (2020) 136 (5): 526–527.

https://doi.org/10.1182/blood.2020005591

Published: 2020

Journal Articles

Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles

Blood (2020) 135 (3): 181–190.

https://doi.org/10.1182/blood.2019000560

Published: 2020

Includes: Supplemental data

Journal Articles

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Vindi Jurinovic, PhD, Verena Passerini, PhD, Mikkel Z Oestergaard, PhD, Andrea Knapp, PhD, Kirsten Mundt, PhD, Shamzah Araf, MRCP, MBBS, PhD, Julia Richter, PhD, Jude Fitzgibbon, PhD, Wolfram Klapper, Robert E. Marcus, FRCP, Andrew Davies, MD PhD, Michael Herold, MD, Wolfgang Hiddemann, PhD, Michael Unterhalt, PhD, Eva Hoster, PhD, Oliver Weigert, MD

Blood (2019) 134 (Supplement_1): 122.

https://doi.org/10.1182/blood-2019-130208

Published: 2019

Journal Articles

Aberrant Cathepsin S Induces a Supportive Immune Microenvironment in Follicular Lymphoma

Blood (2019) 134 (Supplement_1): 657.

https://doi.org/10.1182/blood-2019-122663

Published: 2019

NARROW

Highly Heterogeneous Cellular Composition and Neighborhood Architecture within the Follicular Lymphoma Tumor Microenvironment

High Grade B-Cell Lymphoma with BCL2 and MYC Rearrangement (Double-Hit High-Grade Lymphoma; DH-HGL): Establishment of a Human Model System for Ex Vivo and In Vivo Studies

Real-World Evidence of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide with or without Polatuzumab (VIPOR(P)) for Relapsed/Refractory Large B-Cell Lymphoma

Lysosomal Membrane Permeabilization Sensitizes Ctss-Hyperactive Tumors to BCL2-Targeting Therapies

Identification of High-Risk Population in First-Line Follicular Lymphoma at Screening with a Next Generation Sequencing (NGS) Assay Using Plasma Circulating Tumor DNA (ctDNA): Initial Data from Gallium

Genomic profiling for clinical decision making in lymphoid neoplasms

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

An EZH2 Gene Expression Signature Is Predictive of Differential Efficacy of Chemotherapy Irrespective of EZH2 Mutation Status in Patients with Follicular Lymphoma Treated within the Gallium Trial

Treatment-Free Intervals during CD19xCD3 BiTE ® Construct-Mediated T-Cell Stimulation Induce Functional Reinvigoration and Transcriptional Reprogramming of Exhausted T Cells

ARID1A Controls a Novel Transcriptional Network Regulating FAS in Follicular Lymphoma

Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (NCT#03269669): SWOG S1608

CHOP but Not Bendamustine Reverses EZH2 Y641 Mutation Induced MHC-I/II Loss in Human Lymphoma Models

An Inducible Leukemia-Associated Transcription Factor Facilitates Large-Scale Ex Vivo Generation of Functional Human Macrophages

Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma

Treatment-Free Intervals Mitigate T-Cell Exhaustion Induced By Continuous CD19xCD3-BiTE® Construct Stimulation in Vitro

The different flavors and splices of MCL

Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Aberrant Cathepsin S Induces a Supportive Immune Microenvironment in Follicular Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only